Chemicals & Biochemicals

(S)-3-Hydroxybutyric acid

NEW
(S)-3-Hydroxybutyric acid

Article No

AG-CR1-3617-M025

Size

25 mg

Source / Host

synthetic

Product insert

Specifications

CAS No 6168-83-8
MW 104.1
Additional Information Optical Rotation: [alpha]20/D c=6 in H2O: 25°±1.0°
Article No AG-CR1-3617-M025
Description (S)-3-Hydroxybutyric acid
Supplier Adipogen Life Sciences
Format Powder
Notes Physiologically insignificant stereoisomer of (R)-3-Hydroxybutyric acid, a key metabolite of the ketolytic pathway. Anticonvulsant. Endogenous inhibitor of histone deacetylases (HDACs) 1, 3 and 4. Ligand of free fatty acid receptor 3 (FFAR3; GPR41) and hydroxycarboxylic acid receptor 2 (HCAR2; GPR109B). NLRP3 inflammasome inhibitor. Prevents K+-efflux and reduces ASC oligomerization and speck formation.
Molecular Formula C4H8O3
Alias Names (S)-beta-Hydroxybutyric acid; L-(+)-3-Hydroxybutyric acid; L-(+)-BHB
Product Type Chemicals & Biochemicals
Protocol Optical Rotation: [alpha]20/D c=6 in H2O: 25°±1.0°
Purity >98% (TLC)
References Effects of beta-hydroxy butyric acid on insulin binding to its receptor and on autophosphorylation of the receptor: H. Ohtusaka, et al.; Endocrinol. Jpn. 37, 915 (1990) | Acetoacetate, acetone, and dibenzylamine (a contaminant in L-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo: J.M. Rho, et al.; Epilepsia 43, 358 (2002) | The direct measurement of 3-beta-hydroxy butyrate enhances the management of diabetic ketoacidosis in children and reduces time and costs of treatment: M. Vanelli, et al.; Diabetes Nutr. Metab. 16, 312 (2003) | Detection of cerebral {beta}-hydroxy butyrate, acetoacetate, and lactate on proton MR spectroscopy in children with diabetic ketoacidosis: S.L. Wootton-Gorges, et al.; AJNR 26, 1286 (2005) | beta-Hydroxybutyrate activates the NF-kappaB signaling pathway to promote the expression of pro-inflammatory factors in calf hepatocytes: X. Shi, et al.; Cell. Physiol. Biochem. 33, 920 (2014) | beta-hydroxybutyrate: Much more than a metabolite: J. C. Newman & E. Verdin; Diab. Res. Clin. Pract. 106, 173 (2014) (Review) | BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-kappaB activation: S.P. Fu, et al.; Med. Inflamm. 2014, ID983401 (2014) | Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms: S.P. Fu, et al.; J. Neuroinflamm. 12, ID9 (2015) | The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease: Y.H. Youm, et al.; Nat. Med. 21, 263 (2015) | Taming the inflammasome: M. Levy, et al.; Nat. Med. 21, 213 (2015) | Inflammasome inhibition: putting out the fire: M.G. Netea & L.A. Joosten; Cell Metab. 21, 513 (2015) | Inflammasome: starving inflammation: E. Kugleberg; Nat. Rev. Immunol. 15, 199 (2015) (Review) | The Nlrp3 inflammasome admits defeat: C.J. Gross & O. Gross; Trends Immunol. 36, 323 (2015) (Review)
Research Area Metabolism
Size 25 mg
Solubility Soluble in water, 100% ethanol or methanol.
Source / Host synthetic
Stability Stable for at least 2 years after receipt when stored at -20°C.
Storage -20°C
Technical Specifications Chemical. CAS: 6168-83-8. Formula: C4H8O3. MW: 104.1. Physiologically insignificant stereoisomer of (R)-3-Hydroxybutyric acid, a key metabolite of the ketolytic pathway. Anticonvulsant. Endogenous inhibitor of histone deacetylases (HDACs) 1, 3 and 4. Ligand of free fatty acid receptor 3 (FFAR3; GPR41) and hydroxycarboxylic acid receptor 2 (HCAR2; GPR109B). NLRP3 inflammasome inhibitor. Prevents K+-efflux and reduces ASC oligomerization and speck formation.
Product Page Updated 2019-07-12T09:17:06.689Z

Shipping info

The delivery time for this item is approximately 5-8 business days. If other deviations occur, this will be noted on the order confirmation or communicated via email. Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.